Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02387177 · ClinicalTrials.gov registry record · NA
Resiliency Training for Adolescent Neurofibromatosis Patients Via Videoconferencing With Skype
A NA study of Neurofibromatoses, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- NA
- Development phase
- 51
- Enrollment target
- 1
- Study location
NCT02387177: Completed NA study of Neurofibromatoses, sponsored by Massachusetts General Hospital.
NCT02387177 is a NA study of Neurofibromatoses that has completed, run by Massachusetts General Hospital. The registered enrollment target is 51 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02387177, a NA study of Neurofibromatoses, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 51 participants
- Enrollment target
- 1
- Study location
Study Summary
The aim of this research is to adapt the NF-specific adult version of the Skype 3RP for use with adolescents, and to test its feasibility, acceptability, and preliminary effect in improving quality of life, and in decreasing stress and psychological distress.
Primary Outcome
Measures quality of life
Conditions Studied
Interventions
- BEHAVIORAL Stress Management Group 1
- BEHAVIORAL Stress Management Group 2
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2015-01 |
| Est. Completion | 2017-12 |
| Phase | NA |
What the finished NCT02387177 record still lists
NCT02387177 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 51 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Neurofibromatoses appearing as the primary indexed condition, and to 2 interventions - of which Stress Management Group 1 is the first listed.
NCT02387177 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02387177 about?
NCT02387177 is a clinical study titled "Resiliency Training for Adolescent Neurofibromatosis Patients Via Videoconferencing With Skype". The aim of this research is to adapt the NF-specific adult version of the Skype 3RP for use with adolescents, and to test its feasibility, acceptability, and preliminary effect in improving quality of life, and in decreasing stress and psychological distress.
What is the current status of trial NCT02387177?
This trial is currently completed. It is a NA study. The enrollment target is 51 participants. The study started on 2015-01. Estimated completion is 2017-12.
What conditions does trial NCT02387177 study?
This clinical trial studies the following conditions: Neurofibromatoses.
What interventions are being tested in trial NCT02387177?
The interventions under investigation include: Stress Management Group 1 (BEHAVIORAL), Stress Management Group 2 (BEHAVIORAL).
Who is sponsoring clinical trial NCT02387177?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02387177 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neurofibromatoses
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02387177's enrollment target sits among peer trials
51 1279th of 2000 higher than 722 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02701153 · 51 participants · NA
Phase II Study of 5-Day Hypofractionated Preoperative Radiation Therapy for Soft Tissue Sarcomas: Expansion Cohort
- NCT03663790 · 51 participants · NA
Effects of Gait Retraining on Lower Extremity Biomechanics
- NCT03874052 · 51 participants · Phase 1
Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
- NCT04704661 · 51 participants · Phase 1
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia